Correlations of genotype and viral load with HCV antibody S/CO ratio,liver enzymes and peripheral blood T lymphocyte subsets among patients with chronic HCV infection in Xinjiang

doi:10.3969/j.issn.1673-8640.2016.12.006

Abstract

Abstract:

Objective To investigate the influence of genotype and viral load on hepatitis C virus（HCV） antibody S/CO ratio,liver enzymes and peripheral blood T lymphocyte subsets among patients with chronic HCV infection in Xinjiang.Methods A total of 106 outpatients and inpatients from the First Affiliated Hospital of Xinjiang Medical University were enrolled from January 2014 to September 2015,and 30 healthy subjects were enrolled as healthy control group. HCV antibody,liver enzymes [alanine aminotransferase（ALT） and aspartate aminotransferase（AST）],HCV RNA,HCV genotype and peripheral blood T lymphocyte subsets were determined by chemiluminescence,enzymatic analysis,fluorescence quantitation reverse transcription polymerase chain reaction（PCR）,PCR-reverse dot blot hybridization and multi-color flow cytometry. Results There was statistical significance in HCV antibody S/CO ratio,ALT and the percentage of CD8⁺T lymphocyte among 1b,2a,3a and 3b genotypes（P<0.05）. The percentages of CD4⁺ T lymphocyte and CD4/CD8 ratio in 1b and 2a genotypes were lower than those in healthy control group [CD4⁺T lymphocyte percentages were（39.05±9.42）%,（38.65±10.26）% and（42.45±4.61）%,and CD4/CD8 ratios were 1.60±0.64,1.53±0.66 and 2.31±0.25],and the percentages of CD8⁺ T lymphocyte [（26.79±7.58）% and（27.15±10.40）%] were higher than those in healthy control group [（18.36±3.88）%,P<0.05]. According to HCV RNA load for classification,there was statistical significance for HCV antibody S/CO ratio,liver enzymes and CD4/CD8 ratio（P<0.05）. Conclusions HCV 1b and 2a genotypes are main genotypes for patients with chronic HCV infection in Xinjiang. Viral load and different genotypes may affect HCV antibody S/CO ratio,liver enzymes and peripheral blood T lymphocyte subsets.

Key words: Genotypes, T lymphocyte subsets, Antibody S/CO ratio, Liver enzymes, Viral load, Hepatitis C

CLC Number:

R446.63

YU Lu, WU Jing, MU Chaodong, HOU Li, ZHANG Zhaoxia. Correlations of genotype and viral load with HCV antibody S/CO ratio,liver enzymes and peripheral blood T lymphocyte subsets among patients with chronic HCV infection in Xinjiang[J]. Laboratory Medicine, 2016, 31(12): 1040-1043.

Figures/Tables 3

References 20

1	TAIEB V,PACOU M,HO S,et al. A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 hepatitis C virus[J]. J Med Econ,2015,18(10):787-796.
2	THOMAS D,ZOULIM F. New challenges in viral hepatitis[J]. Gut,2012,61(Suppl 1):i1-i5.
3	RAMOS B,NÚEZ M,TORO C,et al. Changes in the distribution of hepatitis C virus(HCV) genotypes over time in Spain according to HIV serostatus:implications for HCV therapy in HCV/HIV-coinfected patients[J]. J Infect,2007,54(2):173-179.
4	ASHFAQ UA,JAVED T,REHMAN S,et al. An overview of HCV molecular biology,replication and immune responses[J]. Virol J,2011,8:161.
5	AMINI M,POUSTCHI H. Hepatitis C virus spontaneous clearance:immunology and genetic variance[J]. Viral Immunol,2012,25(4):241-248.
6	中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会. 丙型肝炎防治指南[J]. 中华肝脏病杂志,2004,12(4):194-198.
7	YOON JC,LIM JB,PARK JH,et al. Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells[J]. J Virol,2011,85(23):12557-12569.
8	SCHLAPHOFF V,LUNEMANN S,SUNEETHA PV,et al. Dual function of the NK cell receptor 2B4(CD244) in the regulation of HCV-specific CD8+ T cells[J]. PLoS Pathog,2011,7(5):e1002045.
9	任艳,郑素军,段钟平. 丙型肝炎慢性化的免疫机制研究进展[J]. 中华肝脏病杂志,2013,21(2):151-153.
10	SIMMONDS P,BUKH J,COMBET C,et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J]. Hepatology,2005,42(4):962-973.
11	NAKANO T,LU L,HE Y,et al. Population genetic history of hepatitis C virus 1b infection in China[J]. J Gen Virol,2006,87(Pt 1):73-82.
12	童汪霞,朱建芸,雷姿颖,等. HCV在中国流行多样性和独特生长史的分析[J]. 中华实验和临床病毒学杂志,2014,28(5):336-338.
13	徐也晴,邱丰,徐恩洁,等. 新疆维吾尔族人群丙型肝炎病毒基因分型分布分析[J]. 中华实验和临床病毒学杂志,2014,28(4):265-267.
14	SARHAN MA,PHAM TN,CHEN AY,et al. Hepatitis C virus infection of human T lymphocytes is mediated by CD5[J]. J Virol,2012,86(7):3723-3735.
15	YOU J,ZHUANG L,ZHANG YF,et al. Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load[J]. World J Gastroenterol,2009,15(27):3382-3393.
16	LEE YS,YOON SK,CHUNG ES,et al. The relationship of histologic activity to serum ALT,HCV genotype and HCV RNA titers in chronic hepatitis C[J]. J Korean Med Sci,2001,16(5):585-591.
17	杨小娟,吴国荣. 无锡地区丙型肝炎患者病毒基因型及外周血辅助性T细胞因子表达[J]. 现代检验医学杂志,2012,27(6):73-75.
18	严艳,李卓,郭向华,等. 北京地区慢性丙型肝炎患者血清HCV-RNA定量检测与基因分型的研究[J]. 医学理论与实践,2007,20(7):756-757.
19	CARREO V,BARTOLOMÉ J,CASTILLO I,et al. New perspectives in occult hepatitis C virus infection[J]. World J Gastroenterol,2012,18(23):2887-2894.
20	殷先尧,郑美娟,徐元宏,等. T细胞亚群与慢性丙型肝炎病毒相关性分析[J]. 安徽医科大学学报,2014,60(3):327-330.

HCV基因型	例数	HCV抗体S/CO值	HCV RNA（U/mL）	ALT（U/mL）
1b	56	7.22±3.13	3.95×10⁵（3.40×10⁴~3.24×10⁶）	51.40（25.40~73.10）
2a	29	6.43±2.93	1.21×10⁵（5.37×10⁴~3.42×10⁶）	72.80（29.75~156.68）
3a	11	5.48±3.73	9.73×10⁵（2.74×10⁴~2.00×10⁶）	29.30（24.40~43.10）
3b	10	4.56±2.95	2.32×10⁵（1.23×10⁴~2.63×10⁶）	129.60（34.81~151.55）
统计量		10.61^*	2.75^#	7.338^#
P值		<0.05	0.443	<0.05
HCV基因型	AST（U/mL）	CD4⁺T淋巴细胞百分数（%）	CD8⁺T淋巴细胞百分数（%）	CD4/CD8比值
1b	64.20±61.69	39.05±9.42	26.79±7.58	1.60±0.64
2a	70.37±49.93	38.65±10.26	27.15±10.40	1.53±0.66
3a	52.77±39.96	32.50±4.90	32.65±10.36	1.10±0.44
3b	78.78±74.81	35.22±13.04	35.52±12.15	1.14±0.55
统计量	2.01^*	0.88^*	2.53^*	1.207^*
P值	0.100	0.480	<0.05	0.314

HCV基因型	例数	HCV抗体S/CO值	HCV RNA（U/mL）	ALT（U/mL）
1b	56	7.22±3.13	3.95×10⁵（3.40×10⁴~3.24×10⁶）	51.40（25.40~73.10）
2a	29	6.43±2.93	1.21×10⁵（5.37×10⁴~3.42×10⁶）	72.80（29.75~156.68）
3a	11	5.48±3.73	9.73×10⁵（2.74×10⁴~2.00×10⁶）	29.30（24.40~43.10）
3b	10	4.56±2.95	2.32×10⁵（1.23×10⁴~2.63×10⁶）	129.60（34.81~151.55）
统计量		10.61^*	2.75^#	7.338^#
P值		<0.05	0.443	<0.05
HCV基因型	AST（U/mL）	CD4⁺T淋巴细胞百分数（%）	CD8⁺T淋巴细胞百分数（%）	CD4/CD8比值
1b	64.20±61.69	39.05±9.42	26.79±7.58	1.60±0.64
2a	70.37±49.93	38.65±10.26	27.15±10.40	1.53±0.66
3a	52.77±39.96	32.50±4.90	32.65±10.36	1.10±0.44
3b	78.78±74.81	35.22±13.04	35.52±12.15	1.14±0.55
统计量	2.01^*	0.88^*	2.53^*	1.207^*
P值	0.100	0.480	<0.05	0.314

组别（拷贝/mL）	例数	HCV抗体S/CO值	ALT（U/mL）	AST（U/mL）
HCV RNA<1×10³组	19	1.99±0.59	25.54±12.94	23.34（14.40~38.53）
1×10³≤HCV RNA<1×10⁵组	33	5.74±1.78	65.29±52.95	40.60（25.48~71.35）
1×10⁵≤HCV RNA<1×10⁷组	50	6.75±3.62	70.66±61.60	46.10（27.75~69.75）
HCV RNA≥1×10⁷组	4	9.71±0.50	29.88±15.33	28.80（23.60~51.40）
统计量		14.055^*	3.256^*	12.671^#
P值		<0.05	<0.05	<0.05
组别（拷贝/mL）	CD4⁺T淋巴细胞百分数（%）		CD8⁺T淋巴细胞百分数（%）	CD4/CD8比值
HCV RNA<1×10³组	39.05±9.42		26.79±7.58	1.60±0.64
1×10³≤HCV RNA<1×10⁵组	38.65±10.26		27.15±10.40	1.53±0.66
1×10⁵≤HCV RNA<1×10⁷组	35.58±9.25		28.32±9.48	1.43±0.65
HCV RNA≥1×10⁷组	46.70±5.48		22.86±9.40	2.28±0.97
统计量	2.103^*		0.905^*	2.643^*
P值	0.106		0.442	<0.05

组别（拷贝/mL）	例数	HCV抗体S/CO值	ALT（U/mL）	AST（U/mL）
HCV RNA<1×10³组	19	1.99±0.59	25.54±12.94	23.34（14.40~38.53）
1×10³≤HCV RNA<1×10⁵组	33	5.74±1.78	65.29±52.95	40.60（25.48~71.35）
1×10⁵≤HCV RNA<1×10⁷组	50	6.75±3.62	70.66±61.60	46.10（27.75~69.75）
HCV RNA≥1×10⁷组	4	9.71±0.50	29.88±15.33	28.80（23.60~51.40）
统计量		14.055^*	3.256^*	12.671^#
P值		<0.05	<0.05	<0.05
组别（拷贝/mL）	CD4⁺T淋巴细胞百分数（%）		CD8⁺T淋巴细胞百分数（%）	CD4/CD8比值
HCV RNA<1×10³组	39.05±9.42		26.79±7.58	1.60±0.64
1×10³≤HCV RNA<1×10⁵组	38.65±10.26		27.15±10.40	1.53±0.66
1×10⁵≤HCV RNA<1×10⁷组	35.58±9.25		28.32±9.48	1.43±0.65
HCV RNA≥1×10⁷组	46.70±5.48		22.86±9.40	2.28±0.97
统计量	2.103^*		0.905^*	2.643^*
P值	0.106		0.442	<0.05

组别	例数	CD4⁺T淋巴细胞百分数（%）	CD8⁺T淋巴细胞百分数（%）	CD4/CD8比值
慢性丙型肝炎患者
1b基因型	56	39.05±9.42	26.79±7.58	1.60±0.64
2a基因型	29	38.65±10.26	27.15±10.40	1.53±0.66
正常对照组	30	42.45±4.61	18.36±3.88	2.31±0.25
F值		4.268	4.056	5.676
P值		0.043	0.040	0.030